0001104659-22-111243.txt : 20221025 0001104659-22-111243.hdr.sgml : 20221025 20221025173233 ACCESSION NUMBER: 0001104659-22-111243 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221021 FILED AS OF DATE: 20221025 DATE AS OF CHANGE: 20221025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tosca Melissa CENTRAL INDEX KEY: 0001947184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 221330529 MAIL ADDRESS: STREET 1: C/O KIORA PHARMACEUTICALS, INC. STREET 2: 1371 EAST 2100 SOUTH, SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 BUSINESS PHONE: (781) 788-8869 MAIL ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 4 1 tm2228925-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-10-21 0 0001372514 KIORA PHARMACEUTICALS INC KPRX 0001947184 Tosca Melissa C/O KIORA PHARMACEUTICALS, INC 1371 E. 2100 SOUTH, SUITE 200 SALT LAKE CITY UT 84105 0 1 0 0 EVP of Finance Common Stock 2022-10-21 4 A 0 2500 0 A 2500 D Stock Option (right to buy) 6.78 2022-10-21 4 A 0 5000 0 A 2032-10-21 Common Stock 5000 5000 D Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the reporting person's continuous service through each such vesting date. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on September 13, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. /s/ Melissa Tosca 2022-10-25